AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12617381
Drug: Additional upper
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional upper limb physiotherapy (115 minutes, twice per day)
Trial: 12617381
Drug: Wrist extension
RxNorm normalized name: EXTENSION TUBES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wrist extension measurement (twice daily with an electrogoniometer for 3-4 weeks)
Trial: 10669898
Drug: Diclofenac injection
RxNorm normalized name: diclofenac Injection
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac injection (75 mg)
Trial: 10669898
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations of diclofenac (suppository and injection)
Trial: 26922827
Drug: Electroconvulsive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive therapy (ECT) for 4 weeks
Trial: 23243977
Drug: Rotation/Oscillation power
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotation/Oscillation power toothbrush (Oral‐B Triumph with SmartGuide)
Trial: 18520610
Drug: Thrombin receptor
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombin receptor activating peptide-induced platelet aggregation
Trial: 2197345
Drug: Both strains
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both strains (highest doses)
Trial: 24015984
Drug: Internet-based smartphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based smartphone application for self-control training (modified Stroop-task) delivered daily over 4 weeks
Trial: 15849809
Drug: Proglumide treatment
RxNorm normalized name: proglumide
DrugBank: Proglumide (DB13431)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proglumide treatment group (0.4 g proglumide thrice daily for more than 5 years)
Trial: 12745495
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal nicotine (OT‐NIC) lozenge (4 mg)
Trial: 11056094
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitors or AT1-R antagonists
Trial: 4034622
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg methylphenidate hydrochloride (Ritalin)
Trial: 4034622
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg methylphenidate hydrochloride (Ritalin)
Trial: 4034622
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg methylphenidate hydrochloride (Ritalin)
Trial: 30382891
Drug: Personalized dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized dosage of morphine during the procedure when VAS ≥4
Trial: 30382891
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of morphine intravenously, followed by 10 mg of morphine subcutaneously 30 min before surgery (Control group)
Trial: 26808848
Drug: 12 g
RxNorm normalized name: PEG-12 GLYCERYL LAURATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 g of citrulline-malate (CM)
Trial: 22458601
Drug: Hawthorn extract
RxNorm normalized name: hawthorn extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hawthorn extract (1000 mg, 1500 mg, and 2500 mg)
Trial: 8580690
Drug: Chinese medicinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicinal herbs and chemotherapy on the first postoperational day
Trial: 8580690
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment two weeks later (Control)
Trial: 384024
Drug: 2 mg.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg. butorphanol
Trial: 384024
Drug: 4 mg.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg. butorphanol
Trial: 384024
Drug: 80 mg.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg. meperidine
Trial: 19467415
Drug: Tongue base
RxNorm normalized name: beef tongue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongue base suspension
Trial: 19467415
Drug: Obese patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obese patients (tongue base suspension)
Trial: 17612946
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS 30 mg/day (bedtime dosing)
Trial: 17612946
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS 60 mg/day (bedtime dosing)
Trial: 17612946
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS (bedtime dosing)
Trial: 17612946
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS 30 mg/day (morning dosing)
Trial: 11750840
Drug: Oral topotecan,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral topotecan, 2.3 mg/m(2)/day for 5 days every 21 days
Trial: 11750840
Drug: Intravenous topotecan,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous topotecan, 1.5 mg/m(2)/day for 5 days every 21 days
Trial: 8984044
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose PRP-T vaccine
Trial: 8984044
Drug: Associated with
RxNorm normalized name: Blood group antigen associated with but not included in MNS system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Associated with DPT vaccine
Trial: 7448509
Drug: Antiseptic skin
RxNorm normalized name: Antiseptic Skin Cleanser
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antiseptic skin preparation and daily care of the cannula site
Trial: 7448509
Drug: No skin
RxNorm normalized name: Aveeno Skin Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No skin preparation before or after cannula insertion
Trial: 3539614
Drug: Tiapamil 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiapamil 800 mg
Trial: 11213009
Drug: Two percent
RxNorm normalized name: LIDOCAINE HYDROCHLORIDE 20 mg in 1 mL TOPICAL SPRAY [Lidotral Two Percent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two percent lignocaine gel
Trial: 11213009
Drug: Inert gel
RxNorm normalized name: inert ingredients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert gel (placebo)
Trial: 29191649
Drug: 0.375% ropivacaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.375% ropivacaine, 20 mL plus 1 μg/kg of dexmedetomidine (group RD)
Trial: 29191649
Drug: 0.375% ropivacaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.375% ropivacaine, 20 mL only (group R)
Trial: 21438413
Drug: Pingchuan water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pingchuan water decoction (one tie per day, in four to six-divided doses for eight weeks)
Trial: 21438413
Drug: Montelukast Sodium
RxNorm normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast Sodium tablets (4 mg for 2-5 years old or 5 mg for 6-14 years old, once every night before sleeping for eight weeks)
Trial: 17682119
Drug: Glucosamine (500
RxNorm normalized name: poly(N-acetyl, N-arginyl)glucosamine (50000-80000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucosamine (500 mg orally three times daily for 2 weeks)
Trial: 17682119
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 mg orally three times daily for 2 weeks)
Trial: 10426383
Drug: 24-h Acipimox
RxNorm normalized name: acipimox
DrugBank: Acipimox (DB09055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-h Acipimox (250 mg/4 h)
Trial: 2124986
Drug: 5 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 micrograms plasma vaccine Pasteur (containing 1% pre-S2)
Trial: 2124986
Drug: 20 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms plasma vaccine MSD (no pre-S2)
Trial: 21972820
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate (DE) 110 mg twice daily
Trial: 21972820
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate (DE) 150 mg twice daily
Trial: 21972820
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate (DE) 75 mg twice daily (simulated for severely renally impaired patients)
Trial: 11350844
Drug: Intramuscular gold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular gold (GST)
Trial: 9394106
Drug: Paromomycin sulfate
RxNorm normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paromomycin sulfate (3 x 1 g/day)
Trial: 7699154
Drug: Pefloxacin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin (800 mg i.v. OD for 4 days)
Trial: 7699154
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with teicoplanin (800 mg i.v. OD) and netilmicin (300 mg i.m. OD)
Trial: 7699154
Drug: Thymostimulin (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymostimulin (70 mg i.m. OD for the first month and every other day thereafter until discharge)
Trial: 31188232
Drug: Dose reduction
RxNorm normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reduction group (n = 17)
Trial: 31188232
Drug: Dose maintenance
RxNorm normalized name: XCOPRI 250mg Daily Dose Maintenance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose maintenance group (n = 18)
Trial: 19201696
Drug: tamsulosin 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tamsulosin 0.8 mg once daily (QD)
Trial: 19201696
Drug: alfuzosin 10
RxNorm normalized name: Alfuzosin 10mg Oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfuzosin 10 mg QD
Trial: 8777471
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg + Placebo
Trial: 8777471
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg + HCTZ 6.25 mg
Trial: 8777471
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg + HCTZ 12.5 mg
Trial: 8777471
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg + HCTZ 25 mg
Trial: 1538443
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (20 micrograms/ml)
Trial: 1538443
Drug: Papaverine hydrochloride
RxNorm normalized name: Papaverine Hydrochloride
DrugBank: Papaverine (DB01113)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Papaverine hydrochloride (30 mg/ml)
Trial: 17823448
Drug: 4 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/d of 78% active CLA isomers (3.2 g/d: 39.2% cis‐9,trans‐11 and 38.5% trans‐10,cis‐12)
Trial: 17823448
Drug: 4 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/d of safflower oil (placebo)
Trial: 17823448
Drug: 4 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/d of 78% active CLA isomers
Trial: 10709412
Drug: Class III
RxNorm normalized name: HLA class III antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Class III drugs (sotalol and amiodarone)
Trial: 2183505
Drug: Systemic treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic treatment with cyclosporin A (CSA) at a dosage of 2.5 mg/kg/d for 10 weeks
Trial: 2183505
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of cyclosporin A (CSA) in 1/5/10% gel and ointment
Trial: 31079328
Drug: 0.0 mg
RxNorm normalized name: RUXOLITINIB 10.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0 mg of chromium picolinate (CrPic) supplementation per ewe (T1)
Trial: 31079328
Drug: 0.15 mg
RxNorm normalized name: iodine 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg of CrPic per ewe (T2)
Trial: 31079328
Drug: 0.30 mg
RxNorm normalized name: Corona Multi-Purpose 0.30 MG/MG Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.30 mg of CrPic per ewe (T3)
Trial: 31079328
Drug: 0.45 mg
RxNorm normalized name: urea 0.45 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45 mg of CrPic per ewe (T4)
Trial: 29803838
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (through-the-scope clips and thermal therapy plus injection with diluted adrenaline)
Trial: 1662376
Drug: Monoclonal anti-CD3
RxNorm normalized name: Anti-CD3
DrugBank: Muromonab (DB00075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal anti-CD3 antibody
Trial: 7049955
Drug: Standard combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard combination of neomycin, cephaloridin, polymyxin B or E and nystatin or amphotericin B
Trial: 30724002
Drug: Licogliflozin 150
RxNorm normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licogliflozin 150 mg q.d. for 12 weeks
Trial: 30724002
Drug: Licogliflozin 300
RxNorm normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licogliflozin 300 mg single dose prior to OGTT
Trial: 30724002
Drug: Licogliflozin 15
RxNorm normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licogliflozin 15 mg q.d. for 14 days
Trial: 29871676
Drug: Data on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Data on drug therapy, utilization of health services, and medical expenses
Trial: 25985582
Drug: Letosteine (50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letosteine (50mg thrice daily)
Trial: 25985582
Drug: Ambroxol hydrochloride
RxNorm normalized name: AMBROXOL HYDROCHLORIDE
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol hydrochloride (30mg thrice daily)
Trial: 17145784
Drug: Ofloxacin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (20 mg/kg/day for 7 days)
Trial: 17145784
Drug: Ofloxacin-Azithromycin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin-Azithromycin (15 mg/kg/day of ofloxacin for 7 days and 10 mg/kg/day of azithromycin for the first 3 days)
Trial: 17145784
Drug: Azithromycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (10 mg/kg/day for 7 days)
Trial: 15807195
Drug: Statins (HMG-CoA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statins (HMG-CoA reductase inhibitors)
Trial: 12113133
Drug: Irradiation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiation and chemotherapy
Trial: 8056571
Drug: Alternate Treatment
RxNorm normalized name: Target Alternate Site Lancet 26G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate Treatment Control (ATC)
Trial: 2468913
Drug: Verapamil (VER,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (VER, 240 mg/day)
Trial: 2468913
Drug: Nifedipine (NIF,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (NIF, 40 mg/day)
Trial: 21070775
Drug: Peginterferon and
RxNorm normalized name: peginterferon alfa-2a Injection [Pegasys]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon and ribavirin therapy
Trial: 9242972
Drug: Cafestol (61-64
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cafestol (61-64 mg/day)
Trial: 9242972
Drug: Cafestol (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cafestol (60 mg/day) and kahweol (48-54 mg/day)
Trial: 28983994
Drug: HIT+β2 A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIT+β2 A (daily inhalation of β2 ‐agonist terbutaline, 4 mg dose-1)
Trial: 28983994
Drug: HIT (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIT (high intensity training without β2 ‐agonist)
Trial: 22621750
Drug: Short-term adjunctive
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term adjunctive subantimicrobial dose doxycycline (SDD)
Trial: 19546674
Drug: 1.5 mL
RxNorm normalized name: Humulin 70/30 1.5 ML Pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mL 0.25% bupivacaine
Trial: 15336473
Drug: Combined typhoid
RxNorm normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined typhoid fever/HAV vaccine (3 batches)
Trial: 12575377
Drug: Shenqi tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenqi tablet (SQT)
Trial: 2723122
Drug: Slow-release potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release potassium citrate tablets (60 meq)
Trial: 2723122
Drug: Rapid-release liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid-release liquid potassium citrate preparation (60 meq)
Trial: 4888876
Drug: Propranolol 30
RxNorm normalized name: HCTZ 25/PROPRANOLOL 30MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 30 mg twice daily
Trial: 25427171
Drug: Topiramate (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (300 mg/d)
Trial: 25427171
Drug: Levetiracetam (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (2000 mg/d)
Trial: 21666939
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (ALA) 300 mg daily
Trial: 19948518
Drug: Dexamethasone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (1 mg/kg at induction of anesthesia and 0.5 mg/kg 8 hours later)
Trial: 9145958
Drug: Glycolic acid
RxNorm normalized name: Glycolic Acid
DrugBank: Glycolic acid (DB03085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycolic acid peels (68% maximum concentration) in addition to 2% hydroquinone/10% glycolic acid gel twice daily and 0.05% tretinoin cream at night.
Trial: 9145958
Drug: 2% hydroquinone/10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% hydroquinone/10% glycolic acid gel twice daily and 0.05% tretinoin cream at night (control group).
Trial: 3144300
Drug: Chlormethiazole 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormethiazole 250 mg
Trial: 3144300
Drug: Chlormethiazole 500
RxNorm normalized name: chlormethiazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormethiazole 500 mg
Trial: 25604900
Drug: 50 mg/day
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/day DHEA
Trial: 24326568
Drug: Bimatoprost 0.03%
RxNorm normalized name: BIMATOPROST 0.03% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimatoprost 0.03% solution, applied once daily to the upper eyelid margin for 6 months
Trial: 24326568
Drug: Bimatoprost 0.03%
RxNorm normalized name: BIMATOPROST 0.03% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimatoprost 0.03% solution
Trial: 18077316
Drug: All hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All hormonal treatments (E(2), E(2) + MPA, Tibolone)
Trial: 16518347
Drug: BNP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNP with ET-B receptor antagonist BQ-788 (50 nmol/min)
Trial: 16518347
Drug: BQ-788 infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BQ-788 infusion
Trial: 3324800
Drug: Naloxone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone treatment
Trial: 24281361
Drug: Cognitive Remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Remediation Therapy (CRT) plus Treatment as Usual (TAU)
Trial: 18251623
Drug: Ziprasidone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone (mean daily dose 84.1 mg/day, SD = 54.8; range, 40-200)
Trial: 16825332
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (100 mg for women; 200 mg for men)
Trial: 14657829
Drug: Intramuscular iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular iron
Trial: 14657829
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron (3 months)
Trial: 11016326
Drug: Additional heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional heparin
Trial: 9001875
Drug: Cefonicid 1
RxNorm normalized name: cefonicid 1 g injectable powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefonicid 1 g given by intravenous infusion 30 minutes before the operation
Trial: 30231106
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine 266 mg
Trial: 24886402
Drug: Day Hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day Hospital Mentalization-Based Treatment (MBT-DH)